Real-time Estimate
Cboe BZX
01:47:04 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
9.075
USD
|
-0.27%
|
|
-8.81%
|
-61.01%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
167.6
|
99.56
|
414.9
|
119.3
|
1,088
|
474
|
-
|
-
|
Enterprise Value (EV)
1 |
167.6
|
99.56
|
414.9
|
119.3
|
806.6
|
264.5
|
190.5
|
113.7
|
P/E ratio
|
-2.87
x
|
-1.86
x
|
-6.03
x
|
-1.28
x
|
-12.7
x
|
-3.89
x
|
-2.83
x
|
-2.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.23
x
|
2.89
x
|
11.2
x
|
2.88
x
|
23.6
x
|
10.9
x
|
35.5
x
|
49.5
x
|
EV / Revenue
|
8.23
x
|
2.89
x
|
11.2
x
|
2.88
x
|
17.5
x
|
6.06
x
|
14.3
x
|
11.9
x
|
EV / EBITDA
|
-4.12
x
|
-2.87
x
|
-
|
-
|
-
|
1.38
x
|
0.9
x
|
0.42
x
|
EV / FCF
|
-2.94
x
|
-6.73
x
|
-8.26
x
|
-1.78
x
|
-502
x
|
-2.13
x
|
-1.39
x
|
-0.9
x
|
FCF Yield
|
-34%
|
-14.9%
|
-12.1%
|
-56.3%
|
-0.2%
|
-46.9%
|
-72%
|
-111%
|
Price to Book
|
-
|
-
|
-
|
-
|
4.26
x
|
2.79
x
|
2.15
x
|
1.96
x
|
Nbr of stocks (in thousands)
|
10,812
|
15,130
|
33,894
|
34,083
|
47,074
|
52,084
|
-
|
-
|
Reference price
2 |
15.50
|
6.580
|
12.24
|
3.500
|
23.11
|
9.100
|
9.100
|
9.100
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.36
|
34.44
|
36.94
|
41.4
|
46.02
|
43.63
|
13.35
|
9.575
|
EBITDA
1 |
-40.69
|
-34.64
|
-
|
-
|
-
|
191.5
|
210.6
|
271.7
|
EBIT
1 |
-47.86
|
-37.29
|
-55.28
|
-78.94
|
-75.07
|
-131
|
-175.1
|
-207.4
|
Operating Margin
|
-235.02%
|
-108.28%
|
-149.64%
|
-190.65%
|
-163.13%
|
-300.31%
|
-1,311.84%
|
-2,166.22%
|
Earnings before Tax (EBT)
1 |
-56.79
|
-45.39
|
-58.42
|
-102.3
|
-70.71
|
-119.9
|
-170.3
|
-204.6
|
Net income
1 |
-56.79
|
-45.39
|
-58.42
|
-102.3
|
-70.8
|
-120.3
|
-173.6
|
-214.6
|
Net margin
|
-278.88%
|
-131.82%
|
-158.14%
|
-246.97%
|
-153.84%
|
-275.75%
|
-1,300.59%
|
-2,241.37%
|
EPS
2 |
-5.400
|
-3.540
|
-2.030
|
-2.740
|
-1.820
|
-2.341
|
-3.210
|
-3.381
|
Free Cash Flow
1 |
-56.91
|
-14.8
|
-50.25
|
-67.16
|
-1.608
|
-124
|
-137.2
|
-125.7
|
FCF margin
|
-279.46%
|
-42.97%
|
-136.04%
|
-162.19%
|
-3.49%
|
-284.2%
|
-1,027.61%
|
-1,313.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
11.54
|
9.294
|
11.56
|
10.01
|
10.53
|
7.683
|
9.105
|
15.2
|
14.03
|
11.68
|
9.594
|
9.259
|
8.968
|
10.85
|
10.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
46
|
49
|
52
|
-
|
-
|
EBIT
1 |
-18.05
|
-18.28
|
-19.22
|
-18.4
|
-23.04
|
-21.55
|
-22.76
|
-14.4
|
-16.35
|
-33.32
|
-29.36
|
-31.94
|
-34.96
|
-22.4
|
-25.4
|
Operating Margin
|
-156.36%
|
-196.73%
|
-166.16%
|
-183.76%
|
-218.7%
|
-280.54%
|
-249.98%
|
-94.71%
|
-116.58%
|
-285.18%
|
-306.03%
|
-345%
|
-389.79%
|
-206.45%
|
-241.9%
|
Earnings before Tax (EBT)
1 |
-19.43
|
-20.98
|
-19.41
|
-18.42
|
-43.45
|
-21.16
|
-22.92
|
-12.61
|
-14.02
|
-29.28
|
-27.18
|
-29.95
|
-33.5
|
-22.4
|
-25.4
|
Net income
1 |
-19.43
|
-20.98
|
-19.41
|
-18.42
|
-43.45
|
-21.16
|
-22.92
|
-12.61
|
-14.1
|
-29.28
|
-27.18
|
-29.95
|
-33.5
|
-22.4
|
-25.4
|
Net margin
|
-168.33%
|
-225.69%
|
-167.8%
|
-183.98%
|
-412.53%
|
-275.47%
|
-251.73%
|
-82.96%
|
-100.51%
|
-250.63%
|
-283.29%
|
-323.48%
|
-373.5%
|
-206.45%
|
-241.9%
|
EPS
2 |
-0.5900
|
-0.5600
|
-0.5200
|
-0.4900
|
-1.160
|
-0.5600
|
-0.6100
|
-0.3300
|
-0.3300
|
-0.5500
|
-0.5314
|
-0.5868
|
-0.6626
|
-0.4450
|
-0.4800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/4/22
|
8/3/22
|
11/2/22
|
3/2/23
|
5/3/23
|
8/2/23
|
11/1/23
|
3/7/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
281
|
209
|
284
|
360
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-56.9
|
-14.8
|
-50.3
|
-67.2
|
-1.61
|
-124
|
-137
|
-126
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-39%
|
-56%
|
-92.7%
|
-91.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-26.4%
|
-42.1%
|
-72.6%
|
-74.4%
|
Assets
1 |
-
|
-
|
-
|
-
|
267.8
|
285.9
|
239.2
|
288.3
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
5.430
|
3.270
|
4.230
|
4.640
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.21
|
0.36
|
0.16
|
2.15
|
3.48
|
2.87
|
2.43
|
3.4
|
Capex / Sales
|
1.05%
|
1.05%
|
0.42%
|
5.19%
|
7.57%
|
6.57%
|
18.23%
|
35.51%
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Average target price
38.44
USD Spread / Average Target +322.47% Consensus |
1st Jan change
|
Capi.
|
---|
| -61.01% | 474M | | +47.34% | 765B | | -6.56% | 354B | | +19.82% | 331B | | +9.00% | 299B | | +18.87% | 248B | | -1.96% | 219B | | +11.11% | 216B | | +5.10% | 164B | | -2.57% | 162B |
Other Pharmaceuticals
|